Ikarian Capital, LLC Biogen Inc. Transaction History

Ikarian Capital, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$252.44 - $306.72 $2.52 Million - $3.07 Million	-10,000 Reduced 91.22%	962 $266,000
Q3 2022 Nov 14, 2022	BUY	$194.69 - $268.46 $1.92 Million - $2.64 Million	9,840 Added 877.01%	10,962 $2.93 Million
Q1 2022 May 13, 2022	SELL	$193.77 - $244.14 $5.51 Million - $6.94 Million	-28,411 Reduced 96.2%	1,122 $237,000
Q4 2021 Feb 14, 2022	SELL	$223.92 - $287.77 $606,823 - $779,856	-2,710 Reduced 8.4%	29,533 $7.09 Million
Q3 2021 Nov 15, 2021	SELL	$282.99 - $369.05 $26.5 Million - $34.6 Million	-93,719 Reduced 74.4%	32,243 $9.12 Million
Q2 2021 Aug 16, 2021	BUY	$259.0 - $414.71 $31.1 Million - $49.9 Million	120,262 Added 2109.86%	125,962 $43.6 Million
Q4 2020 Feb 12, 2021	BUY	$236.26 - $355.63 $637,902 - $960,201	2,700 Added 90.0%	5,700 $1.4 Million
Q3 2020 Nov 16, 2020	BUY	$264.77 - $305.71 $583,817 - $674,090	2,205 Added 277.36%	3,000 $852,000
Q1 2020 May 15, 2020	BUY	$268.85 - $341.04 $213,735 - $271,126	795 New	795 $252,000

1,018

128M

1.22M

1.4M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.